tbuckley/cabot-search huggingface dataset:
In Vitro Assessment of Commercial Contraceptive Jellies and Creams
Authors: John MacLeod
Journal: JAMA (1961)

Fifty-four commercial contraceptive jellies and creams were evaluated for sperm-immobilizing capacity by 3 laboratory technics. Observations were made within 20 seconds after the contraceptive preparation had been mixed with human semen of good quality. For each preparation the median of the 3 results was taken as a measure of its effectiveness, and the wide range of median results indicated considerable disparity in the effectiveness of the preparations. Satisfactory coefficients of correlation were obtained when the 3 laboratory technics were studied for reliability, but it was not possible to determine their validity. Such a determination, involving correlation between laboratory values and clinical measures of effectiveness, is not possible at present.
Association of prostaglandin‐endoperoxide synthase 2 gene polymorphisms with asthma and atopy in Chinese children
Authors: I. H. S. Chan, N. L. S. Tang, T. F. Leung, S. L. Ma, Y. P. Zhang, G. W. K. Wong, C. K. Wong, C. W. K. Lam
Journal: Allergy (2007)

Background: Cyclooxygenase‐2 (COX‐2) plays essential roles in inflammation. Previous studies have suggested associations between prostaglandin‐endoperoxide synthase 2 ( PTGS2 ) polymorphisms and prostaglandins production in asthma. Objective: We have investigated the effects of Chinese tagging single nucleotide polymorphisms (SNPs) of PTGS2 on asthma traits in 299 Chinese asthmatic children and 175 controls. Methods: Plasma total and allergen‐specific IgE were measured by enzyme immunoassay. PTGS2 .8473T→C in the 3′‐untranslated region of exon 10 and three tag SNPs covering most of the variations in PTGS2 haplotypes in Chinese were genotyped by restriction fragment length polymorphism. Results: Among the four SNPs, only PTGS2 .8473 showed significant association with asthma ( P = 0.034) and atopy ( P = 0.005 when compared with non‐atopic controls; P = 0.023 with all controls). Carriers of the C allele had a 1.5‐fold (95% confidence interval: 1.01–2.30) risk of developing asthma than those homozygous for the T allele. Multivariate regression revealed significant correlations between PTGS2 .8473 and forced expiratory volume in 1 s (FEV 1 ; P = 0.002) and peak expiratory flow rate (PEFR; P = 0.001) with age and gender adjusted. Patients with the C allele of PTGS2 .8473 had significantly lower FEV 1 (median: 90.0% vs 98.0%; P = 0.0047) and PEFR (70.0% vs 73.5%; P = 0.0065) than those homozygous for the T allele. No significant association between plasma total and allergen‐specific IgE and these SNPs or with their haplotypes was found. Conclusions: PTGS2 .8473 polymorphism is associated with asthma, atopy and lung function but not plasma IgE in Chinese children. This may help to explore the pharmacogenetics of COX‐2 inhibitors.
Increased chemokine receptor CCR7/EBI1 expression enhances the infiltration of lymphoid organs by adult T-cell leukemia cells
Authors: Hitoshi Hasegawa, Tetsuhiko Nomura, Masashi Kohno, Norihiko Tateishi, Yoji Suzuki, Nobuji Maeda, Ryuichi Fujisawa, Osamu Yoshie, Shigeru Fujita
Journal: Blood (2000)
Learning to Breathe
Authors: Elizabeth Levin
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype
Authors: Xu-Rong Jiang, Gretchen Jimenez, Edwin Chang, Maria Frolkis, Brenda Kusler, Marijke Sage, Michelle Beeche, Andrea G. Bodnar, Geoffrey M. Wahl, Thea D. Tlsty, Choy-Pik Chiu
Journal: Nature Genetics (1999)
Medicine and the Reign of Technology.
Authors: Stanley Joel Reiser
Journal: Annals of Internal Medicine (1979)

Book Reviews literature, but also on a detailed survey of the objects on which the literature was based, by a practised histologist familiar with the longer-lasting techniques.The result is an attractively-produced book containing a wealth of illustrations from a wide range of sources, including pictures of old preparations made through the microscope as well as microtomes in use.Over a thousand literature references are included, making the book a gold-mine for all interested in microscopical history.
Maternal Uniparental Isodisomy of Chromosome 6 Reveals a TULP1 Mutation as a Novel Cause of Cone Dysfunction
Authors: Susanne Roosing, L. Ingeborgh van den Born, Carel B. Hoyng, Alberta A.H.J. Thiadens, Elfride de Baere, Rob W.J. Collin, Robert K. Koenekoop, Bart P. Leroy, Norka van Moll-Ramirez, Hanka Venselaar, Frans C.C. Riemslag, Frans P.M. Cremers, Caroline C.W. Klaver, Anneke I. den Hollander
Journal: Ophthalmology (2013)
RE-LY and RELY-ABLE : Long-term Follow-up of Patients With Non-valvular Atrial Fibrillation Receiving Dabigatran Etexilate for Up to 6.7 Years
Authors: Michael D. Ezekowitz, Anthony P. Kent, Janice Pogue, Paul A. Reilly, Martina Brueckmann, Andreas Clemens, Salim Yusuf, Lars Wallentin, Stuart J. Connolly
Journal: Circulation (2013)

RE-LY and RELY-ABLE : Long-term Follow-up of Patients With Non-valvular Atrial Fibrillation Receiving Dabigatran Etexilate for Up to 6.7 Years
Lower Digestive Tract.
Authors: Frank Henry Netter, Ernst Oppenheimer, Geigy Pharmaceuticals
Journal: Annals of Internal Medicine (1962)

PART I Upper Digestive Tract SECTION 1 Overview of Upper Digestive Tract SECTION 2 Mouth and Pharynx SECTION 3 Esophagus SECTION 4 Stomach ISBN: 978-1-4557-7390-9 PART II Lower Digestive Tract SECTION 1 Overview of the Lower Digestive Tract SECTION 2 Small Bowel SECTION 3 Colon ISBN: 978-1-4557-7391-6 PART III Liver, Biliary Tract, and Pancreas SECTION 1 Liver SECTION 2 Gallbladder and Bile Ducts SECTION 3 Pancreas ISBN: 978-1-4557-7392-3
You Have the Power
Authors: R D Orr
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cognitive Behavioral Therapy for Insomnia Comorbid With Psychiatric and Medical Conditions
Authors: Jade Q. Wu, Erica R. Appleman, Robert D. Salazar, Jason C. Ong
Journal: JAMA Internal Medicine (2015)

Cognitive behavioral therapy for insomnia (CBT-I) is the most prominent nonpharmacologic treatment for insomnia disorders. Although meta-analyses have examined primary insomnia, less is known about the comparative efficacy of CBT-I on comorbid insomnia.To examine the efficacy of CBT-I for insomnia comorbid with psychiatric and/or medical conditions for (1) remission from insomnia; (2) self-reported sleep efficiency, sleep onset latency, wake after sleep onset, total sleep time, and subjective sleep quality; and (3) comorbid symptoms.A systematic search was conducted on June 2, 2014, through PubMed, PsycINFO, the Cochrane Library, and manual searches. Search terms included (1) CBT-I or CBT or cognitive behavioral [and its variations] or behavioral therapy [and its variations] or behavioral sleep medicine or stimulus control or sleep restriction or relaxation therapy or relaxation training or progressive muscle relaxation or paradoxical intention; and (2) insomnia or sleep disturbance.Studies were included if they were randomized clinical trials with at least one CBT-I arm and had an adult population meeting diagnostic criteria for insomnia as well as a concomitant condition. Inclusion in final analyses (37 studies) was based on consensus between 3 authors' independent screenings.Data were independently extracted by 2 authors and pooled using a random-effects model. Study quality was independently evaluated by 2 authors using the Cochrane risk of bias assessment tool.A priori main outcomes (ie, clinical sleep and comorbid outcomes) were derived from sleep diary and other self-report measures.At posttreatment evaluation, 36.0% of patients who received CBT-I were in remission from insomnia compared with 16.9% of those in control or comparison conditions (pooled odds ratio, 3.28; 95% CI, 2.30-4.68; P < .001). Pretreatment and posttreatment controlled effect sizes were medium to large for most sleep parameters (sleep efficiency: Hedges g = 0.91 [95% CI, 0.74 to 1.08]; sleep onset latency: Hedges g = 0.80 [95% CI, 0.60 to 1.00]; wake after sleep onset: Hedges g = 0.68; sleep quality: Hedges g = 0.84; all P < .001), except total sleep time. Comorbid outcomes yielded a small effect size (Hedges g = 0.39 [95% CI, 0.60-0.98]; P < .001); improvements were greater in psychiatric than in medical populations (Hedges g = 0.20 [95% CI, 0.09-0.30]; χ2 test for interaction = 12.30; P < .001).Cognitive behavioral therapy for insomnia is efficacious for improving insomnia symptoms and sleep parameters for patients with comorbid insomnia. A small to medium positive effect was found across comorbid outcomes, with larger effects on psychiatric conditions compared with medical conditions. Large-scale studies with more rigorous designs to reduce detection and performance bias are needed to improve the quality of the evidence.
<i>In vitro</i> detection and characterization of drug hypersensitivity using flow cytometry
Authors: M. Martin, G. Wurpts, H. Ott, J. M. Baron, S. Erdmann, H. F. Merk, B. Sachs
Journal: Allergy (2009)

The lymphocyte transformation test (LTT) is the only in vitro test for detecting drug sensitization at the cellular level irrespective of the reaction's phenotype. However, the LTT includes working with radioactive substances and is considered impracticable for routine laboratory investigation.The aim of this study was to assess drug-specific cytokine production by means of flow cytometry as an alternative nonradioactive approach which may be more appropriate for routine testing and may provide in addition more information about the pathophysiology of the reaction than proliferation-based assays, like the LTT.Peripheral blood mononuclear cells of 19 patients were incubated with culprit drugs (n = 28) or irrelevant antigens (n = 10). Ten healthy persons served as controls for all different drugs (n = 15). Intracellular interleukin (IL)-5, interferon (IFN)-gamma and IL-10 production was investigated using flow cytometry. Accuracy of the flow cytometry test system was confirmed using different statistical tests, i.e. receiver operating characteristic curve and Mann-Whitney rank test. In addition, drug-specific secretion of IL-5, IL-2 and IFN-gamma were analysed using enzyme-linked immunosorbent assay (ELISA).Drug-specific cytokine production could be demonstrated in 75% of the patients using flow cytometry and in 79% using ELISA respectively. Combining ELISA and flow cytometry increased the sensitivity to 100%. Analysis of involved T-cell subsets [e.g. CD4(+) or CD8(+); T helper (TH) 1 or TH 2] allowed characterization of the in vitro lymphocyte reactivity pattern.Analysis of drug-specific cytokine production by means of flow cytometry proved a useful and reliable approach for the in vitro detection and characterization of drug hypersensitivities.
And the poor get children
Authors: Donald W MacCorquodale
Journal: BMJ (2003)

From BMJ USA 2003;April:230 

Even though I heard the lecture more than 57 years ago, I still remember Dr T Leon Howard's words on interstitial cystitis. In his delightful southern drawl, he began, “You've just fallen asleep, and somebody starts poking you in the back and saying, ‘Get up and go pee; get up and go pee' and that goes on all night long.”

I remember other lectures not quite so earthily phrased: a dour pharmacologist on the convulsions of strychnine poisoning; an ill-tempered obstetrician on the mechanisms of labor; and a courtly internist on the signs and symptoms of aortic insufficiency.

I do not remember a single mention of abortion by any member of the faculty …
Abstract 18594: Efficacy of Dabigatran versus Warfarin in Patients With Acute Venous Thromboembolism and Thrombophilia: A Pooled Analysis of RE-COVER™ and RE-COVER™ II
Authors: Sam Schulman, Henry Eriksson, Samuel Z Goldhaber, Ajay Kakkar, Clive Kearon, Patrick Mismetti, Martin Feuring, Stefan Hantel, Joerg Kreuzer, Sebastian Schellong
Journal: Circulation (2014)

Objectives:  In the RE-COVER™ and RE-COVER™ II trials, dabigatran etexilate (DE) compared with warfarin in patients with acute venous thromboembolism (VTE) resulted in similar rates of recurrent VTE/VTE-related death with fewer bleeding events. From the pooled RE-COVER™ and RE-COVER™ II trial data, we assessed the hypothesis that the efficacy of DE versus warfarin would be similar in the subgroup of patients with thrombophilia, a known risk factor for VTE recurrence.   Methods:  In both studies, patients with symptomatic proximal deep vein thrombosis or pulmonary embolism (PE) were randomized to warfarin or warfarin-placebo plus parenteral anticoagulation for ≥ 5 days until the international normalized ratio (INR) was ≥ 2 at two consecutive measurements. Parenteral therapy was then discontinued and patients continued warfarin (target INR range 2.0-3.0) or received DE 150 mg twice-daily for 6 months (double-dummy, oral-only treatment period). The primary efficacy outcome was recurrent, symptomatic, objectively confirmed VTE/VTE-related death from randomization up to the end of the prespecified post-treatment follow-up (6 months + 30 days). Outcomes were centrally adjudicated.   Results:  Overall, 209/2553 (8.2%) patients randomized to DE and 199/2554 (7.8%) randomized to warfarin had thrombophilia identified at baseline; Factor V Leiden thrombophilia was the most common type (Table). The frequency of VTE/VTE-related deaths or of PE was lower with DE versus warfarin in patients with thrombophilia, but was not statistically different (Table). The treatment efficacy was not significantly affected by the presence of thrombophilia.   Conclusions:  In patients with acute VTE and thrombophilia, there was a lower frequency of VTE/VTE-related deaths or of PE with DE versus warfarin, but the difference was not statistically significant. The treatment efficacy was not significantly affected by the presence of thrombophilia.
Abstract 13989: Distinguishing Focal Fibrotic Lesions and Non-Fibrotic Lesions in Hypertrophic Cardiomyopathy by Assessment of Regional Myocardial Strain using Two-Dimensional Speckle Tracking Echocardiography: Comparison with Multislice CT
Authors: Akihisa Kataoka, Nobusada Funabashi, Kwanghow Lee, Rei Yajima, Masae Uehara, Marehiko Ueda, Issei Komuro
Journal: Circulation (2010)

Purpose: In hypertrophic cardiomyopathy (HCM), focal fibrotic lesions are frequently observed in magnetic resonance imaging or multislice CT (MSCT). The presence of fibrotic lesions may be associat...
Abstract 16402: Feasibility of Combined Evaluation of Brain Natriuretic Peptide and Heart-Type Fatty Acid Binding Protein in Female Patients with Heart Failure
Authors: Hiromasa Hasegawa, Tetsu Watanabe, Nobuyuki Kiribayashi, Toshiki Sasaki, Yohichiroh Ohtaki, Shintaro Honda, Shunsuke Netsu, Akira Funayama, Mitsunori Ishino, Hiroki Takahashi, Takanori Arimoto, Tetsuro Shishido, Takehiko Miyashita, Takuya Miyamoto, Joji Nitobe, Isao Kubota
Journal: Circulation (2010)

Background: Heart failure (HF) in women remains poorly recognized and poorly understood syndrome. The objective of this work is to investigate sex differences in etiology, diagnosis and prognostic ...
Abstract P333: Diabetes: Coronary Heart Disease Risk Equivalent or Risk Factor? The REasons for Geographic and Racial Differences in Stroke Study
Authors: Favel L Mondesir, Todd M Brown, Paul Muntner, Raegan W Durant, Monika M Safford, Emily B Levitan
Journal: Circulation (2015)

Evidence is mixed regarding whether diabetes confers an equivalent risk of coronary heart disease (CHD) as prior myocardial infarction (MI). We assessed the hypotheses that 1) diabetes is a CHD risk equivalent and 2) severe diabetes is a CHD risk equivalent in the REasons for Geographic and Racial Differences in Stroke study population (30,239 black and white US adults ≥ 45 years recruited 2003-2007 with follow-up through 2011 for CHD). Diabetes at baseline was assessed using blood glucose (fasting ≥ 126 mg/dL or non-fasting ≥ 200 mg/dL) or self-reported use of diabetes medication. CHD at baseline was assessed using electrocardiogram evidence of MI or self-report of MI or revascularization. The primary exposure groups were diabetes only, CHD only, both diabetes and CHD, and neither CHD nor diabetes at baseline. We further stratified individuals with diabetes only at baseline by self-reported insulin use or albuminuria (urinary albumin-to-creatinine ratio ≥ 30 mg/g) to identify more severe diabetes. We con...
46. Clinical and Functional Recovery from Experimental Autoimmune Encephalomyelitis by Intracisternal Delivery of IL4 from a Helper-Dependent Adenoviral Vector. A Pre-Clinical Model of Gene Therapy of Multiple Sclerosis
Authors: Erica Butti, Alessandra Recchia, Alessandra Bergami, Anna Stornaiuolo, Elena Brambilla, Roberto Furlan, Gianvito Martino, Fulvio Mavilio
Journal: Molecular Therapy (2004)

Widespread demyelination, axonal loss and permanent neurological impairment are hallmarks of chronic, inflammatory demyelinating disorders of the CNS, such as multiple sclerosis (MS). The multifocal, recurrent nature of MS complicates cell and gene therapy approaches aimed at restoring axonal conduction by inducing re-myelination, or transplanting myelin-forming cells, at the sites of injury. Previous studies have demonstrated that systemic delivery of the anti-inflammatory cytokine IL4 to the CNS through the cerebro-spinal fluid circulation can prevent demyelination in experimentally-induced autoimmune encephalomyelitis (EAE), a murine model of MS (Hum Gene Ther 8:13, 2001). We have established a cytokine-delivery system to the CNS by transducing the ependimal layer lining the ventricular system with fully deleted, helper-dependent adenoviral vectors (HD-Ad). A single injection of a HD-Ad vector expressing IL-4 and GFP (AdIL-4G) into the cisterna magna of immunocompetent mice is sufficient to transduce ependimal and leptomeningeal cells surrounding ventricular and sub-arachnoid spaces. Vector DNA and GFP expression were detected in ependimal and leptomeningeal cells by real-time PCR after laser-capture microdissection and immunohystochemistry up to five months after injection. IL-4 levels up to 340 pg/ml were measured by ELISA in the cerebrospinal fluid five months after treatment. Serum IL-4 levels were always below detection limits. To assess the therapeutic potential of intracysternal IL-4 delivery, 30 mice affected by myelin oligodendrocyte glycoprotein (MOG35-55)-induced EAE were injected the day of clinical onset with escalating doses (105 to 107 i.p./mouse) of AdIL-4G or a control HD-Ad vector expressing only GFP. Mice treated with >106 i.p. of AdIL-4G displayed a progressive clinical recovery, and 80 days after immunization had an average EAE score of 1.0 (±1.0) vs. 1.62 (±0.4) in control mice (p<0.05). Motor evoked potentials (MEP) were recordable in 50% of the control mice, and in all but one of the IL-4-treated mice (p<0.05). In mice were MEP were recordable, central conduction time was significant decreased in IL-4 treated vs. control mice (p<0.05). IL-4 gene therapy by intracisternal administration of HD-Ad vectors therefore induces clinical and functional recovery in a murine model of MS. Biodistribution, immunological and toxicity studies in non-human primates are currently in progress.
Risk of diffuse large B‐cell lymphoma after solid organ transplantation in the United States
Authors: Todd M. Gibson, Eric A. Engels, Christina A. Clarke, Charles F. Lynch, Dennis D. Weisenburger, Lindsay M. Morton
Journal: American Journal of Hematology (2014)

Non‐Hodgkin lymphoma arising in the context of immunosuppression is an important adverse outcome after solid organ transplantation. Diffuse large B‐cell lymphoma (DLBCL) is the most commonly diagnosed subtype of post‐transplantation non‐Hodgkin lymphoma, but few studies of transplant recipients have examined subtype‐specific risks. Therefore, we examined DLBCL risk in the Transplant Cancer Match Study, including registry‐based cancer ascertainment among 96,615 solid organ transplants performed from 2000 to 2008. We determined standardized incidence ratios (SIRs) and 95% confidence intervals comparing DLBCL risk in transplant recipients with that in the general population, and used multivariable Poisson regression models to assess the impact of potential risk factors. We identified 321 incident cases of DLBCL, over 12 times more than expected based on general population rates (SIR = 12.6, 95% confidence interval = 11.2–14.0). SIRs were highest in young recipients and those receiving a lung or pancreas/kidney–pancreas transplant, and were greatly elevated for extranodal DLBCLs at the site of the transplantation compared with other sites. DLBCL risk was highest in the first year following transplantation, and SIRs for early‐onset DLBCL risk were elevated in association with Epstein‐Barr virus‐negative serostatus and use of polyclonal antibody induction therapy. In conclusion, associations between recipient and transplant factors and post‐transplantation DLBCL risk suggest a complicated interrelationship among multiple risk factors and timing of disease. Am. J. Hematol. 89:714–720, 2014. © 2014 Wiley Periodicals, Inc.